Canton Strategic Holdings (CNTN) Non-Current Deferred Tax Liability (2025 - 2026)
Canton Strategic Holdings posted quarterly Non-Current Deferred Tax Liability of $113.7 million for Q1 2026, down 3.58% on a QoQ basis from $117.9 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $113.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $113.7 million; the trailing twelve-month figure through Mar 2026 stood at $113.7 million (changed N/A YoY), and the FY2025 full-year result was $117.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $113.7 million, down from $117.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $117.9 million in Q4 2025 and bottomed at $113.7 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113.71 Mn |
| Mar 31, 2026 | 113.71 Mn |
| Dec 31, 2025 | 117.93 Mn |
| Dec 31, 2025 | 117.93 Mn |